Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Fellows Forum Case Report: Neuromyelitis Optica

Atul Kapila, MD, Tayseer Haroun, MBBS, & Jayanth Doss, MD  |  April 19, 2017

Case Presentation The patient was a 42-year-old African American female diagnosed with systemic lupus erythematosus (SLE) based on the findings of polyarthritis, malar and discoid rash, fatigue, positive double-stranded DNA (dsDNA) ribonucleoprotein and Smith antibodies, and low serum complement levels. Her SLE had been well controlled on hydroxychloroquine 400 mg daily, oral methotrexate 25 mg…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportcentral nervous systemClinicalDevic's diseaseDiagnosiseyeFellowsFellows Foruminflammatory syndromeneuromyelitis opticaoutcomerheumatologyTreatmentvision

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Sneha Patel, MD, Monica Mohile, MD, & Arundathi Jayatilleke, MD  |  April 19, 2017

A 56-year-old African American man presents to the emergency department with polyarthralgias and a fever of 103ºF. One month prior to admission, he presented with right knee pain and swelling. Blood cultures grew S. epidermidis. He was treated for presumed septic arthritis complicated by MSSE bacteremia. He was treated with meropenem and a prolonged course…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:anchoring biasArthritiscase reportClinicalDiagnosisdiagnostic testingGoutinflammationjointoutcomepatient carepolyarthralgiaRArheumatologistrheumatologyseropositive rheumatoid arthritisTreatment

Rheumatology Case Report: Deep Vein Thrombosis Detected by Point-of-Care Ultrasound

Alvin Lee Day, MD, James W. Fant Jr., MD, & Michael Wagner, MD, FACP, RDMS  |  April 18, 2017

Case A 46-year-old Caucasian female presented to the outpatient rheumatology clinic where she had been followed for several years. Her chief complaint was pain in her right knee, posterior right thigh and right hip that had begun gradually over the previous three weeks. Her past medical history was significant for rheumatoid arthritis (RA), obesity and…

Filed under:ConditionsRheumatoid Arthritis Tagged with:case reportClinicaldeep vein thrombosisDiagnosisDVTimagingoutcomepatient carePOCUSpoint-of-careRARheumatoid arthritisrheumatologyTestTreatmentUltrasoundvenous thromboembolism

U.S. FDA Declines to Approve Eli Lilly & Incyte Arthritis Drug

Reuters Staff  |  April 17, 2017

WASHINGTON (Reuters) – The U.S. Food and Drug Administration (FDA) on Friday declined to approve a new drug for rheumatoid arthritis made by Eli Lilly and Co and partner Incyte Corp, the companies said on Friday. The FDA indicated that additional clinical data was needed to determine the most appropriate doses of the drug, baricitinib…

Filed under:Biologics/DMARDsDrug Updates Tagged with:baricitinibFDAFood and Drug AdministrationJanus Kinase Inhibitors

Intimacy & Rheumatic Conditions

Karen Appold  |  April 14, 2017

The side effects of rheumatic conditions and their treatments can cause symptoms some may find awkward or embarrassing to discuss with their physicians. But Ara Dikranian, MD, says rheumatologists must address intimacy issues, both physical and emotional, with all patients…

Filed under:Conditions Tagged with:intimacylifestylepatient carepatient communicationrelationshipsex

U.S. & Europe Evaluate Abaloparatide Injection & Europe Approves Marketing Baricitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  April 11, 2017

Injectable abaloparatide is being evaluated in the U.S. and Europe to treat postmenopausal women with osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatidebaricitinibJanus Kinase InhibitorsOsteoporosispostmenopauseWomen

Sirukumab Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  April 4, 2017

In a clinical trial, RA patients on sirukumab experienced decreased disease activity and improved physical function…

Filed under:Drug Updates Tagged with:Rheumatoid Arthritis (RA)sirukumab

Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain

Arthritis Care & Research  |  April 2, 2017

The clinical practice guidelines for managing Sjögren’s syndrome, developed by the Sjögren’s Syndrome Foundation with the ACR, were designed to improve quality and consistency of care. In total, 19 recommendations were agreed on, which include managing the rheumatic and systemic aspects of the disease. Recommendations include a decision tree for the use of DMARDs for inflammatory musculoskeletal pain, use of self-care measures and exercise to reduce fatigue, and the use of rituximab in selected clinical settings for oral and ocular dryness…

Filed under:ConditionsResearch RheumSjögren’s Disease Tagged with:Arthritis Care & ResearchClinical Practice GuidelinesfatigueMusculoskeletalrituximabsiccaSjogren's

Ustekinumab Has Longer Efficacy Duration than TNFIs for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 28, 2017

When compared with TNFIs, ustekinumab demonstrated a longer drug survival rate in patients with severe plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:biologic drugsdrug survivalplaque psoriasisustekinumab

Immune System Targeted for Research into New Rheumatoid Arthritis Treatments

Thomas R. Collins  |  March 20, 2017

WASHINGTON, D.C.—Researchers at the 2016 ACR/ARHP Annual Meeting discussed how they are exploring the immune system in search of groundwork for new rheumatoid arthritis (RA) treatments. The new avenues, supported by the Rheumatology Research Foundation, involve T cell adhesion, new understanding of the role of macrophages and insights into the way IgG glycans function. T…

Filed under:Meeting ReportsResearch RheumRheumatoid Arthritis Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)IgG glycansImmune SystemmacrophagePathogenesisResearchRheumatoid arthritisrheumatologyT cell adhesionTreatment

  • « Previous Page
  • 1
  • …
  • 60
  • 61
  • 62
  • 63
  • 64
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences